BioCentury
ARTICLE | Finance

Shedding red

Biotech winners, losers in 2Q16

July 11, 2016 7:00 AM UTC

Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps finished in the red for the second quarter in a row, this time shedding 0.4% in 2Q16.

Just like 1Q16, a European biotech paced the big caps. This time it was Genmab A/S, which added 33% in 2Q16, finishing with a market cap of $10.5 billion...